Infections requiring antibiotics, including type, course length, and percentage of excess treatment
| System infected | Infection | Number of patients | Median inpatient antibiotic duration days (range days) | Median total antibiotic course days (course length range in days) | Trust recommended duration (days) | Median days of therapy received for infection / recommended (percentage excess) |
|---|---|---|---|---|---|---|
| Skin and soft tissue | Dog bite | 1 | 3 (NA) | 10 (10) | 7 | 10/7 (43%) |
| Facial cellulitis | 2 | 4.5 (2–7) | 7 (7) | 10 | 7/10 (–30%) | |
| Orbital cellulitis | 1 | 5 (n/a) | 12 (n/a) | 10 | 12/10 (20%) | |
| Cellulitis | 1 | 15 (n/a) | 15 (n/a) | 7–10 | 15/10 (50%) | |
| Sepsis | Source unknown adult | 7 | 6 (4–11) | 7(5–11) | 7 | 7/7 (0%) |
| Obstetrics | Intrapartum pyrexia | 2 | 2.5 (2–3) | 7.5 (7–8) | 7 | 7.5/7 (7%) |
| Respiratory | HAP | 21 | 7 (2–35) | 8 (6–35) | 7 | 8/7 (14%) |
| IECOPD | 3 | 5 (2–9) | 7 (5–9) | 5 | 7/5 (40%) | |
| Bronchitis | 8 | 5.5 (2–10) | 7 (2–17) | 7 | 7/7 (0%) | |
| Aspiration pneumonia | 1 | 7 (n/a) | 7 (n/a) | 7 | 7/7 (0%) | |
| Gastrointestinal | Diverticulitis | 4 | 4 (1–4) | 6 (5–8) | 7 | 6/7 (–14%) |
| Intra-abdominal infection | 2 | 5.5 (5–6) | 9 (5–13) | 7 | 9/7 (28%) | |
| GDH+ | 1 | 5 (n/a) | 5 (n/a) | n/a | n/a | |
| Cholangitis | 3 | 4 (4–6) | 6 (4–11) | 7 | 6/7 (–14%) | |
| Cholecystitis | 3 | 4 (3–7) | 6 (5–15) | 7 | 6/7 (–14%) | |
| ENT | Mastoiditis | 1 | 3 (n/a) | 13 (n/a) | 7–14 | Within range |
| Acute otitis media | 1 | 2 (n/a) | 12 (n/a) | 7 | 12/7 (71%) | |
| Others | Joint replacement, prophylaxis | 1 | 6 (n/a) | 6 (n/a) | 1 | 6/1 (600%) |
| Suspected neonatal sepsis | 1 | 3 (n/a) | 3 (n/a) | 48 hours then review | n/a | |
| Diabetic foot | 1 | 7 (n/a) | n/a | Up to 3 months | Within range | |
| Multiple lung abscesses | 1 | 2 (n/a) | 13 (n/a) | 14 Seek micro advice | n/a | |
| Surgical wound infection | 1 | 11 (n/a) | 11 (n/a) | 48 hours then review | n/a | |
| Tooth infection | 1 | 9 (n/a) | 9 (n/a) | 7 | 9/7 (28%) | |
| Cystic fibrosis exacerbation | 1 | 27 (n/a) | 27 (n/a) | 14 | 27/14 (93%) | |
| Orchitis | 1 | 5 (n/a) | 12 (n/a) | 14 | 12/14 (–14%) | |
| Tubo-ovarian abscess | 1 | 3 | 5 (n/a) | 7 | 5/7 (–29%) | |
| Severe CAP | 10 | - | 8.5 (3–31) | 7–10 | 8.5/10 (–15%) | |
| Non-severe CAP | 23 | - | 9 (3–24) | 5–7 | 9/7 (29%) | |
| Lower UTI | 1 | - | 3 (n/a) | 3 | n/a | |
| Upper UTI | 5 | - | 4 (3–15) | 7–10 | 4/10 (–60%) | |
| CAUTI | 5 | - | 5 (3–10) | 7 | 5/7 (–29%) |
CAP = community-acquired pneumonia; CAUTI = catheter-associated urinary tract infection; CF = cystic fibrosis; GDH = glutamic acid dehydrogenase (C difficile); HAP = hospital-acquired pneumonia; IECOPD = infective exacerbation of chronic obstructive disease; UTI = urinary tract infection, NA = not available